Drug Profile
Research programme: oncolytic virus - TILT Biotherapeutics
Alternative Names: Adv-5/3-d24-TNF-IL2; O-AdLatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator TILT Biotherapeutics
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Sep 2023 Preclinical development is ongoing in Cancer in Finland (TILT Biotherapeutics pipeline, September 2023)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in Finland
- 06 Sep 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (AACR-2017)